Formulation and evaluation of Mucoadhesive film for the Treatment of Migraine

The purpose of this research work is to formulate and evaluate Mucoadhesive film by using Zolmitriptan. It is an triptan group, that relieves the migraine, when pro-inflammatory neuropeptide reease.  It is a Biopharmaceutics Classification System(BCS), which is a classification system that categorizes drugs based on their solubility and permeability properties. BCS class II drugs are characterized by high permeability but low solubility.  The mucoadhesive film formulation was studied using HPMC K4M polymers, Carbopol 934 and poly ethylene glycol used as plasticizer. There are three levels, i.e. were studied for mucoadhesive strength, swelling index, in-vitro drug release and in-vitro residence time.  Preformulation study was carried out includes drug excipients compatibility study, drug estimation method and melting point determination.  The drug estimation was found to be linear between 3 to 25 μg/ml and λmax was found to be 222 nm.  The FTIR spectrum of drug-excipient was found to be satisfactory, which indicated that excipients were compatible with the drug. Zolmitriptan mucoadhesive films were prepared by solvent casting method with different concentration of excipients Carbopol 934 (0.5-2%) and HPMC K4M (3-6%).The mucoadhesive strength of the films was found in the range of 9.95-23.095%, In-vitro residence time 80-247 min, swelling index 12.79-30.2%, In-vitro drug release at 7thhr 93.099%. Among the nine formulations F3 was selected as optimized formulation.